Adherence to isoniazid preventive therapy among child contacts in Rwanda: A mixed-methods study

dc.contributor.authorBirungi, Francine Mwayuma
dc.contributor.authorGraham, Stephen Michael
dc.contributor.authorUwimana, Jeannine
dc.date.accessioned2021-07-06T09:22:13Z
dc.date.available2021-07-06T09:22:13Z
dc.date.issued2019
dc.description.abstractThe World Health Organization recommends isoniazid preventive therapy (IPT) for six months for child contacts without tuberculosis (TB), who are exposed to an adult with active TB. The effectiveness of IPT depends on 80% or greater adherence to medication. In the current study, we assessed IPT adherence and explored barriers to and facilitators of adherence among eligible child contacts in Kigali, Rwanda.A mixed method study design was used to prospectively assess adherence to IPT among eligible child contacts and its associated factors through a quantitative, observational cohort study, and to explore barriers to and facilitators of adherence to IPT through a descriptive qualitative study.en_US
dc.identifier.citationBirungi, F.M. et al., 2019). Adherence to isoniazid preventive therapy among child contacts in Rwanda: A mixed-methods study. PLoS ONE, 14(2), 1–16. https://doi.org/10.1371/journal.pone.0211934en_US
dc.identifier.issn1932-6203
dc.identifier.urihttps://doi.org/10.1371/journal.pone.0211934
dc.identifier.urihttp://hdl.handle.net/10566/6360
dc.language.isoenen_US
dc.publisherPublic Library of Scienceen_US
dc.subjectIsoniaziden_US
dc.subjectTherapyen_US
dc.subjectChild contactsen_US
dc.subjectRwandaen_US
dc.subjectTuberculosis (TB)en_US
dc.subjectPoverty and relocationen_US
dc.titleAdherence to isoniazid preventive therapy among child contacts in Rwanda: A mixed-methods studyen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
pone.0211934.pdf
Size:
940.64 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: